Skip to main content
. Author manuscript; available in PMC: 2016 Feb 27.
Published in final edited form as: Biochem Pharmacol. 2014 Sep 28;92(3):448–456. doi: 10.1016/j.bcp.2014.09.015

Fig. 3.

Fig. 3

Effect of μOR-δOR heteromer-selective antibody on eluxadoline-mediated signaling. Cells (5000 cells) expressing either μβgalOR (A) or μβgalOR-δOR (B) were treated with either deltorphin II (Delt II), loperamide or eluxadoline (1 μM final concentration) in the absence or presence of antibodies (Ab, 1 μg/well) to either μOR, μOR-δOR heteromer or CB1R-AT1R heteromer for 60 min at 37 °C and β-arrestin recruitment was measured as described in Section 2. Results are the mean ± S.E.M. n = 4. *p < 0.05, **p < 0.01, vs. no Ab treatment for each group, Dunnett’s test.